Eurofins Scient (OTCMKTS:ERFSF) Hits New 12-Month High – Time to Buy?

Eurofins Scient (OTCMKTS:ERFSF)’s stock price reached a new 52-week high on Monday . The stock traded as high as $84.8980 and last traded at $84.7860, with a volume of 188 shares changing hands. The stock had previously closed at $78.80.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ERFSF. BNP Paribas raised Eurofins Scient to an “outperform” rating in a research note on Monday, January 5th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Eurofins Scient in a research note on Wednesday, October 29th. Finally, Citigroup restated a “neutral” rating on shares of Eurofins Scient in a research report on Wednesday, October 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

Eurofins Scient Stock Up 8.2%

The company has a current ratio of 1.26, a quick ratio of 1.19 and a debt-to-equity ratio of 0.77. The firm has a 50-day moving average price of $70.86 and a two-hundred day moving average price of $73.20.

Eurofins Scient Company Profile

Eurofins Scientific is a global provider of bioanalytical testing and laboratory services, offering a wide array of testing solutions to pharmaceutical, food, environmental, agriscience and consumer products industries. Its core services include pharmaceutical quality control, environmental testing for water and air quality, food safety analysis, agrochemical trials and clinical diagnostic support. The company operates specialized laboratories equipped with advanced analytical technologies such as chromatography, mass spectrometry and molecular biology to ensure compliance with regulatory standards and to support research and development efforts across multiple sectors.

Founded in 1987 by Gilles Martin and headquartered in Luxembourg, Eurofins has grown through a combination of organic expansion and strategic acquisitions.